SCHEMBL584943

SCHEMBL584943

Fc1cc(Br)cc(F)c1C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.34
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
DGAT1 O75907 1/20 0.31
NOTUM Q6P988 1/20 0.31
SOS1 Q07889 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9014343 0.97 DAO (0.33) DAOCYP11B1CYP11B2DGAT1
SCHEMBL15627263 0.85 CYP11B1 (0.36) CYP11B1CYP11B2NOTUM
SCHEMBL13550081 0.84 PTGS2 (0.30) NOTUM
SCHEMBL30047939 0.84 DGAT1 (0.31) DGAT1
SCHEMBL28906499 0.84 DGAT1 (0.31) DGAT1
SCHEMBL22444782 0.84 NMT1 (0.33) NOTUM
SCHEMBL18099485 0.83 DGAT1 (0.31) DGAT1
SCHEMBL21081880 0.83 TRPV4 (0.45)
SCHEMBL2395180 0.82
SCHEMBL20638975 0.79 ERN1 (0.36) NOTUMSOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117534537-A 3, 5-difluoro-4- (trifluoromethyl) bromobenzene and preparation method thereof 上海药克生物科技有限公司 2024-02-09 CN claimed
CN-117164436-A Method for synthesizing polyfluorophenol by lanthanum cerium copper catalysis 浙江大学衢州研究院 2023-12-05 CN claimed
CN-117024254-A Synthesis method of polyfluorophenol 浙江大学衢州研究院 2023-11-10 CN claimed
EP-4665458-A1 INHIBITING ALPHA V BETA8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 EP disclosed
US-12486449-B2 Organic molecules for use in organic optoelectronic devices SAMSUNG DISPLAY CO., LTD. (KR) 2025-12-02 US disclosed
EP-4603105-A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-20 EP disclosed
EP-4592308-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-30 EP disclosed
CN-120202211-A Cyclic compounds having selective KRAS inhibition over HRAS and NRAS 中外制药株式会社 2025-06-24 CN disclosed
US-20250197450-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-19 US disclosed
CN-113508168-B Compound, liquid crystal medium and liquid crystal display comprising same 默克专利股份有限公司 2025-06-03 CN disclosed
WO-2025085233-A1 NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-04-24 WO disclosed
US-5641432-A USEFUL IN LIQUID CRYSTAL COMPOSITIONS; WIDE LIQUID CRYSTAL PHASE TEMPERATURE RANGE, LOW VISCOSITY, HIGH STABILITY; COMPATIBILITY WITH OTHER LIQUID CRYSTAL COMPOUNDS CHISSO CORPORATION (JP) 1997-06-24 US disclosed
EP-0568040-B1 Cyclohexane derivative and liquid crystal composition containing the same CHISSO CORP (JP) 1996-12-04 EP disclosed
WO-1996037451-A1 LIQUID CRYSTALLINE COMPOUNDS HAVING EXO-METHYLENE SITE AND LIQUID CRYSTAL COMPOSITIONS COMPRISING THE SAME CHISSO CORPORATION (JP) 1996-11-28 WO disclosed
EP-0718264-A1 A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition Chisso Corporation (JP) 1996-06-26 EP disclosed
EP-0688754-A1 DICYCLOHEXYLETHYLENE DERIVATIVE CHISSO CORPORATION (JP) 1995-12-27 EP disclosed
US-5468421-A Cyclohexane derivative and liquid crystal composition containing the same CHISSO CORPORATION (JP) 1995-11-21 US disclosed
EP-0647696-A1 Cyclohexane derivative Chisso Corporation (JP) 1995-04-12 EP disclosed
US-5382379-A Cyclohexane derivative CHISSO CORPORATION (JP) 1995-01-17 US disclosed
EP-0568040-A1 Cyclohexane derivative and liquid crystal composition containing the same CHISSO CORPORATION (JP) 1993-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197450-A1 METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID NPPA, MGMT, ANPEP DAO 94/4885CYP11B1 2403/4885CYP11B2 2802/4885
US-12486449-B2 Organic molecules for use in organic optoelectronic devices OR10J3, OR51E2, OCIAD2 DAO 698/4885CYP11B1 657/4885CYP11B2 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.